BackAlbany Molecular Research Overview

Albany Molecular Research Accounts Payable

Albany Molecular Research's accounts payable is $120M.

Get informed when a big investor buys or sells

+ Follow
Accounts Payable
$116.92M
↑ 61.31% YoYΔ $44.44M vs prior year quarter

Peer average

Loading

Albany Molecular Research Accounts Payable History

Loading

Albany Molecular Research vs. peers: Accounts Payable Comparison

Loading

Albany Molecular Research Accounts Payable Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Albany Molecular Research (AMRI) FAQ

As of the most recent data (June 2017), AMRI shows a accounts payable of $120M. That compares with $72M in the prior-year period — up 61.3% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, AMRI's accounts payable is now $120M (was $72M) — a 61.3% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Albany Molecular Research is outperforming or lagging.

Tracking AMRI's accounts payable over time shows whether Albany Molecular Research is scaling, shrinking, or reshaping that part of the business. The current reading is $120M That compares with $72M in the prior-year period — up 61.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has Albany Molecular Research's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $120M) with ownership activity and broader fundamentals.